Jul. 30 at 9:20 PM
Clear Street🏁
$GPCR Buy-
$61 and said, "We are initiating coverage of Structure Therapeutics with a Buy rating and a
$61 PT, seeing a rare opportunity in the oral drug revolution."
$LLY $VKTX $NVO $TERN AMGN PFE AZN
Clear Street added, "Oral formulations are poised to disrupt the diabesity market, offering efficacy and safety that rivals, if not surpasses, current standards.
$GPCR's lead asset, aleniglipron—a scalable, small-molecule oral GLP-1 inhibitor—could deliver a game-changing POC with P2b data expected by YE25. If results match
$LLY's (LLY, Not Rated) orforglipron (P3 data in 3Q25) and semaglutide, this could be the next major stock catalyst.
Such validation would not only cement
$GPCR's platform as a formidable competitor to peptide drugs, but also spotlight its second asset, ACCG-2671—a first-in-class oral amylin receptor analog with transformative potential, set to spark strategic partnership opportunities.
Clear street additionally said:
